GSK plc has announced that the China National Medical Products Administration has accepted for review the new drug ...

China NMPA accepts for review GSK’s Nucala NDA to treat patients with chronic obstructive pulmonary disease: London, UK Friday, February 21, 2025, 09:00 Hrs [IST] GSK plc announ ...

GSK PLC on Thursday said its monoclonal antibody Nucala, also known as mepolizumab, has been accepted for review in China. The London-based pharmaceutical company said the China Medical Products ...

Mepolizumab reduces asthma exacerbations among real-world patients with severe asthma and an eosinophilic phenotype.

In an office memorandum dated February 17, the nodal agency for price regulation has also directed these companies to issue a ...

Drugs and medicines under Patient Assistance Programmes run by pharmaceutical companies were being made fully exempt from customs duty, provided they are supplied free of cost to patients New ...

Budget 2025: The Finance Minister also informed that the government will exempt basic custom duty on 37 more medicines. (Image Credits: FE) Budget 2025: Finance Minister Nirmala Sitharaman on ...

Cancer patients, including those on patient assistance programmes, can look forward to some relief on their imported medicines. Medicines from multinational companies including Pembrolizumab (MSD ...

Perspectives from John J. Oppenheimer, MD; Sarah Rhoads, MD Of four treatment response measures recorded at 6 months of mepolizumab treatment, an Asthma Control Questionnaire score was deemed ...